Compounds > pm060184
Page last updated: 2024-11-13

pm060184

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

plocabulin: isolated from the sponge Lithoplocamia lithistoides; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID57788271
CHEMBL ID4297636
SCHEMBL ID12895639
MeSH IDM0591236

Synonyms (22)

Synonym
(1z,4s,6z)-1-[(n-{(2z,4z,6e,8s)-8-[(2s)-5-methoxy-6-oxo-3,6-dihydro-2h-pyran-2-yl]-6-methylnona-2,4,6-trienoyl}-3-methyl-l-valyl)amino]octa-1,6-dien-4-yl carbamate
3H4 ,
SCHEMBL12895639
pm-060184
pm060184
2,4,6-nonatrienamide, n-((1s)-1-((((1z,4s,6z)-4-((aminocarbonyl)oxy)-1,6-octadien-1-yl)amino)carbonyl)-2,2-dimethylpropyl)-8-((2s)-3,6-dihydro-5-methoxy-6-oxo-2h-pyran-2-yl)-6-methyl-, (2z,4z,6e,8s)-
52y8l60cr7 ,
960210-99-5
plocabulin [inn]
j3.348.355d ,
unii-52y8l60cr7
plocabulin
plocabulin [who-dd]
DB13137
(1z,4s,6z)-1-[(n-{(2z,4z,6e,8s)-8-[(2s)-5-methoxy-6-oxo-3,6-dihydro-2h-pyran-2-yl]-6-methylnona-2,4,6-trienoyl}-3-methy
l-l-valyl)amino]octa-1,6-dien-4-yl carbamate
[(1z,4s,6z)-1-[[(2s)-2-[[(2z,4z,6e,8s)-8-[(2s)-5-methoxy-6-oxo-2,3-dihydropyran-2-yl]-6-methylnona-2,4,6-trienoyl]amino]-3,3-dimethylbutanoyl]amino]octa-1,6-dien-4-yl] carbamate
Q27261028
CHEMBL4297636
pm 060184
AKOS040749220
(s,1z,6z)-1-((s)-2-((s,2z,4z,6e)-8-((s)-5-methoxy-6-oxo-3,6-dihydro-2h-pyran-2-yl)-6-methylnona-2,4,6-trienamido)-3,3-dimethylbutanamido)octa-1,6-dien-4-yl carbamate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (66.67)24.3611
2020's4 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.05 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
irinotecan
[no description available]		2.2110carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
maytansine
Maytansine: An ansa macrolide isolated from the MAYTENUS genus of East African shrubs.. maytansine : An organic heterotetracyclic compound and 19-membered macrocyclic lactam antibiotic originally isolated from the Ethiopian shrub Maytenus serrata but also found in other Maytenus species. It exhibits cytotoxicity against many tumour cell lines.		2.520alpha-amino acid ester;
carbamate ester;
epoxide;
maytansinoid;
organic heterotetracyclic compound;
organochlorine compound		antimicrobial agent;
antimitotic;
antineoplastic agent;
plant metabolite;
tubulin modulator
rhizoxin
rhizoxin: from Rhizopus chinensis; causal agent of rice seedling blight; structure given in first source. rhizoxin : An macrolide antibiotic isolated from the pathogenic plant fungus Rhizopus microsporus. It also exhibits antitumour and antimitotic activity.		2.5201,3-oxazoles;
epoxide;
macrolide antibiotic		antimitotic;
antineoplastic agent;
metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.4110
Sarcoma, Epithelioid
[description not available]		02.4110
Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.		02.4110
Soft Tissue Neoplasms
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.		02.4110
Benign Neoplasms
[description not available]		03.7730
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		15.7730
Colorectal Cancer
[description not available]		02.2110
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		14.2110
Angiogenesis, Pathologic
[description not available]		02.1710
Breast Cancer
[description not available]		02.110
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.110